mebeverine and lactic acid

mebeverine has been researched along with lactic acid in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abe, K; Egashira, K; Fukuda, K; Kamei, A; Kinjo, A; Kondo, T; Kozuka, C; Masuzaki, H; Morinaga, H; Nakano, K; Shimizu-Okabe, C; Takayama, C; Yasuoka, A	1

Other Studies

1 other study(ies) available for mebeverine and lactic acid

Article	Year
Marked augmentation of PLGA nanoparticle-induced metabolically beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice. Drug delivery, 2017, Volume: 24, Issue:1 Topics: Administration, Oral; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Compounding; Endoplasmic Reticulum Stress; Energy Metabolism; Food Preferences; Gastrointestinal Microbiome; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intestinal Absorption; Islets of Langerhans; Lactic Acid; Lipids; Liver; Male; Mice, Obese; Nanomedicine; Nanoparticles; Obesity; Phenylpropionates; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Technology, Pharmaceutical; Time Factors	2017

Article

Year

Marked augmentation of PLGA nanoparticle-induced metabolically beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice.

Drug delivery, 2017, Volume: 24, Issue:1

Topics: Administration, Oral; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Drug Compounding; Endoplasmic Reticulum Stress; Energy Metabolism; Food Preferences; Gastrointestinal Microbiome; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intestinal Absorption; Islets of Langerhans; Lactic Acid; Lipids; Liver; Male; Mice, Obese; Nanomedicine; Nanoparticles; Obesity; Phenylpropionates; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Technology, Pharmaceutical; Time Factors

2017